Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|November 20, 2024
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future careA John, D J McMahon, D Chauhan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 28, 2025
Feasibility and Outcomes of Craniospinal Irradiation and Concurrent Daily Carboplatin in Children and Adults With High-risk Central Nervous System TumoursR Singer, C Lorimer, L Welsh, et al.
Blood|June 19, 2004
SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsivenessJeffrey S Friedman, Mary F Lopez, Mark D Fleming, et al.
Cell Host & Microbe|May 10, 2024
NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunitsPengcheng Shang, Rita Dos Santos Natividade, Gwen M Taylor, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2024
Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H familyL Gabriel, T McVeigh, S Macmahon, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Gut|January 14, 2005
Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndromeV Johnson, E Volikos, S E Halford, et al.
Anaesthesia|July 12, 2016
Identifying workflow disruptions in the cardiovascular operating roomT N Cohen, J S Cabrera, O D Sisk, et al.
Endocrinology|February 17, 2007
Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretionDamian G Romero, Licy L Yanes, Angela F de Rodriguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancerC Twelves, E Chmielowska, L Havel, et al.
Pageof 18